about
Spotlight on decitabine for myelodysplastic syndromes in Chinese patientsPotential of epigenetic therapies in the management of solid tumorsEpigenome-based personalized medicine in human cancerInhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosisCCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancerDietary components as epigenetic-regulating agents against cancerThe SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.MCM5 as a target of BET inhibitors in thyroid cancer cellsA Novel Quantitative Mass Spectrometry Platform for Determining Protein O-GlcNAcylation Dynamics.A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer.Bromodomain protein Brd3 promotes Ifnb1 transcription via enhancing IRF3/p300 complex formation and recruitment to Ifnb1 promoter in macrophagesChromatin modifications remodel cardiac gene expression.BET-ting on chromatin-based therapeutics for heart failure.Overview of the "epigenetic end points in toxicologic pathology and relevance to human health" session of the 2014 Society Of Toxicologic Pathology Annual Symposium.Epigenetics of the failing heart.Identification and optimization of hydrazone-gallate derivatives as specific inhibitors of DNA methyltransferase 3A.The potential role of PHF6 as an oncogene: a genotranscriptomic/proteomic meta-analysis.Perspective on the dynamics of cancer.Identification of DNA Methylation-Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma.No patient left behind: The promise of immune priming with epigenetic agents.Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.Developmental epigenetic programming of adult germ cell death disease: Polycomb protein EZH2-miR-101 pathway.Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
P2860
Q26778454-5C508F6C-389A-4ACA-BFC8-B66B9F8E5463Q26783134-B98EE923-9EB7-4DB7-AEE6-A6BB2A13AFEBQ28083951-AB2238B5-34CD-456A-A10D-D9281E11ED84Q35147669-BE131A05-C1F5-4451-80E7-8A323DB3E059Q36515055-577E5822-3BA0-4FEA-B94C-644BDFA0B700Q36576975-FB5E67C2-AEB7-4BD2-9983-2C89FCEF7A26Q36584337-6E8A4847-68D1-4421-BE50-0F48DF98BCA4Q36965945-FE01B11E-54A4-4203-B855-0688108AACD3Q37076909-546985FB-0EC4-4C22-823B-FEC5F1ABAC39Q37376258-B50335F5-4202-41E9-8090-D74C8A8D9BADQ37550542-A6A2BB20-6F94-42C7-AD8D-5BB0639CCEE7Q38210525-9C994350-5C8A-4222-9EEF-C52477CB484EQ38212530-64CCB49F-5859-4800-8A16-FD78BBFFAFB3Q38261488-9A5492EA-4D26-4AF2-9E52-F33FE091F0D6Q38408408-B8E778AA-955A-431E-B894-5A3864A2F824Q38786386-2DCF8FE5-2D26-420C-9ED0-A8752263E02CQ40329193-01B8D95D-F601-4108-B786-FEDD8EA84011Q42284422-F510C143-3F63-4417-9112-2D751C8FDB48Q42775763-617C46A9-13B5-4E43-8D34-A2E6C6F78B3CQ46665179-D1AC92AF-E124-47A9-916F-1A5945C9C834Q50071606-A823D7AD-72A5-46D1-8D12-6A2E29367A4BQ50479840-2C1789E5-F056-448E-84DE-38E57D0B4176Q51711294-95A53F0C-10EE-49C0-AF78-F866FAB7A157
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting epigenetic regulators for cancer therapy.
@en
type
label
Targeting epigenetic regulators for cancer therapy.
@en
prefLabel
Targeting epigenetic regulators for cancer therapy.
@en
P2093
P2860
P356
P1476
Targeting epigenetic regulators for cancer therapy.
@en
P2093
Dash Dhanak
Liang Schweizer
Robert A Copeland
Robert Sims
Scott A Armstrong
Stephen B Baylin
P2860
P356
10.1111/NYAS.12356
P407
P577
2014-02-01T00:00:00Z